Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine

Immunogenicity, safety, and efficacy of a tetravalent dengue vaccine in children and adolescents: an analysis by age group

Efficacy and safety of a tetravalent dengue vaccine (TAK-003) in children with prior Japanese encephalitis or yellow fever vaccination

Early onset of protection of the TAK-003 dengue vaccine: Data from the DEN-301 clinical trial

Long term T cell response and safety of a tetravalent dengue vaccine in healthy children

Reply to: Editorial “The increasing use of T-cell stimulation for successful dengue vaccination” in eBioMedicine 2024; 102, 105120

IgG, IgM, and nonstructural protein 1 response profiles after receipt of tetravalent dengue vaccine TAK-003 in a phase 2 randomized controlled trial

Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4.5-year results from a phase 3, randomised, double-blind, placebo-controlled trial

Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adults

An open-label, phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life

Antibodies produced in response to a live-attenuated dengue vaccine are functional in activating the complement system

Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults